Background: Benzodiazepines are a widely used medication in developed countries, particularly among elderly patients. However, benzodiazepines are known to affect memory and cognition and might thus enhance the risk of dementia. The objective of this review is to synthesize evidence from observational studies that evaluated the association between benzodiazepines use and dementia risk. Summary: We performed a systematic review and meta-analysis of controlled observational studies to evaluate the risk of benzodiazepines use on dementia outcome. All control observational studies that compared dementia outcome in patients with benzodiazepine use with a control group were included. We calculated pooled ORs using a random-effects model. Ten studies (of 3,696 studies identified) were included in the systematic review, of which 8 studies were included in random-effects meta-analysis and sensitivity analyses. Odds of dementia were 78% higher in those who used benzodiazepines compared with those who did not use benzodiazepines (OR 1.78; 95% CI 1.33-2.38). In subgroup analysis, the higher association was still found in the studies from Asia (OR 2.40; 95% CI 1.66-3.47) whereas a moderate association was observed in the studies from North America and Europe (OR 1.49; 95% CI 1.34-1.65 and OR 1.43; 95% CI 1.16-1.75). Also, diabetics, hypertension, cardiac disease, and statin drugs were associated with increased risk of dementia but negative association was observed in the case of body mass index. There was significant statistical and clinical heterogeneity among studies for the main analysis and most of the sensitivity analyses. There was significant statistical and clinical heterogeneity among the studies for the main analysis and most of the sensitivity analyses. Key Messages: Our results suggest that benzodiazepine use is significantly associated with dementia risk. However, observational studies cannot clarify whether the observed epidemiologic association is a causal effect or the result of some unmeasured confounding variable. Therefore, more research is needed.

Keywords:
Hypertension, Heterogeneity, Benzodiazepines, Dementia, Diabetic
1.
McCullagh CD, Craig D, McIlroy SP, Passmore AP: Risk factors for dementia. Adv Psychiatr Treat 2001;7:24-31.
2.
Catindig JA, Venketasubramanian N, Ikram MK, Chen C: Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors. J Neurol Sci 2012;321:11-16.
3.
World Health Organization: Dementia: A Public Health Priority. Geneva, World Health Organization, 2012.
4.
Ferri CP, Prince M, Brayne C, et al: Global prevalence of dementia: a Delphi consensus study. Lancet 2006;366:2112-2117.
5.
Plassman BL, Langa KM, Fisher GG, et al: Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007;29:125-132.
6.
Shively S, Scher AI, Perl DP, Diaz-Arrastia R: Dementia resulting from traumatic brain injury: what is the pathology? Arch Neurol 2012;69:1245-1251.
7.
Saczynski JS, Beiser A, Seshadri S, et al: Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology 2010;75:35-41.
8.
Roman GC: Stroke, cognitive decline and vascular dementia: the silent epidemic of the 21st century. Neuroepidemiology 2003;22:161-164.
9.
Kennelly SP, Lawlor BA, Kenny RA: Blood pressure and dementia - a comprehensive review. Ther Adv Neurol Disord 2009;2:241-260.
10.
Linden M, Bär T, Helmchen H: Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE). Int Psychogeriatr 2004;16:461-480.
11.
Rickels K: Should benzodiazepines be replaced by antidepressants in the treatment of anxiety disorders? Fact or fiction? Psychother Psychosom 2013;82:351-352.
12.
Stahl SM: Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 2002;63:756-757.
13.
Mamdani M, Rapoport M, Shulman KI, et al: Mental health-related drug utilization among older adults: prevalence, trends, and costs. Am J Geriatr Psychiatry 2005;13:892-900.
14.
Hogan DB, Maxwell CJ, Fung TS, Ebly EM: Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. Can J Clin Pharmacol 2003;10:72-77.
15.
Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-W94.
16.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
17.
Shih HI, Lin CC, Tu YF, et al: An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study. Medicine (Baltimore) 2015;94:e809.
18.
Imfeld P, Bodmer M, Jick SS, Meier CR: Benzodiazepine use and risk of developing Alzheimer's disease or vascular dementia: a case-control analysis. Drug Saf 2015;38:909-919.
19.
Lagnaoui R, Bégaud B, Moore N, et al: Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 2002;55:314-318.
20.
Billioti de Gage S, Moride Y, Ducruet T, et al: Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ 2014;349:g5205.
21.
Wu CS, Wang SC, Chang IS, Lin KM: The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry 2009;17:614-620.
22.
Wu CS, Ting TT, Wang SC, et al: Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry 2011;19:151-159.
23.
Gray SL, Dublin S, Yu O, et al: Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ 2016;352:i90.
24.
Gallacher J, Elwood P, Pickering J, et al: Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health 2012;66:869-873.
25.
Billioti de Gage S, Bégaud B, Bazin F, et al: Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012;345:e6231.
26.
Shash D, Kurth T, Bertrand M, et al: Benzodiazepine, psychotropic medication, and dementia: a population-based cohort study. Alzheimers Dement 2016;12:604-613.
27.
Higgins JP, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.
28.
Zhong G, Wang Y, Zhang Y, Zhao Y: Association between benzodiazepine use and dementia: a meta-analysis. PLoS One 2015;10:e0127836.
29.
Lara VP, Caramelli P, Teixeira AL, et al: High cortisol levels are associated with cognitive impairment no-dementia (CIND) and dementia. Clin Chim Acta 2013;423:18-22.
30.
Justin BN, Turek M, Hakim AM: Heart disease as a risk factor for dementia. Clin Epidemiol 2013;5:135-145.
31.
Yamada M, Kasagi F, Sasaki H, et al: Association between dementia and midlife risk factors: the radiation effects research foundation adult health study. J Am Geriatr Soc 2003;51:410-414.
32.
Posner HB, Tang MX, Luchsinger J, et al: The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002;58:1175-1181.
33.
Craft S: Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007;4:147-152.
34.
Johansson L, Guo X, Waern M, et al: Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain 2010;133(pt 8):2217-2224.
35.
Higgins JP, Green S: Cochrane Handbook for Systematic Reviews of Interventions. Wiley Online Library, 2008.
36.
Lu L, Fu Dl, Li HQ, et al: Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS One 2014;9:e85781.
37.
Corrada MM, Brookmeyer R, Paganini-Hill A, et al: Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol 2010;67:114-121.
38.
Borenstein AR, Copenhaver CI, Mortimer JA: Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:63-72.
39.
Ptok U, Papassotiropoulos A, Maier W, Heun R: Advanced parental age: a risk factor for Alzheimer's disease or depression in the elderly? Int Psychogeriatr 2000;12:445-451.
40.
Luchsinger JA, Patel B, Tang MX, et al: Measures of adiposity and dementia risk in elderly persons. Arch Neurol 2007;64:392-398.
41.
Fitzpatrick AL, Kuller LH, Lopez OL, et al: Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009;66:336-342.
42.
Peters R, Poulter R, Warner J, et al: Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr 2008;8:36.
43.
Aggarwal NT, Bienias JL, Bennett DA, et al: The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. Neuroepidemiology 2006;26:140-146.
44.
O'Keefe JH, Bybee KA, Lavie CJ: Alcohol and cardiovascular health: the razor-sharp double-edged sword. J Am Coll Cardiol 2007;50:1009-1014.
45.
Luchsinger JA, Tang MX, Siddiqui M, et al: Alcohol intake and risk of dementia. J Am Geriatr Soc 2004;52:540-546.
46.
Xu G, Liu X, Yin Q, et al: Alcohol consumption and transition of mild cognitive impairment to dementia. Psychiatry Clin Neurosci 2009;63:43-49.
47.
Abbott RD, White LR, Ross GW, et al: Walking and dementia in physically capable elderly men. JAMA 2004;292:1447-1453.
48.
Mehlig K, Skoog I, Waern M, et al: Physical activity, weight status, diabetes and dementia: a 34-year follow-up of the population study of women in Gothenburg. Neuroepidemiology 2014;42:252-259.
49.
Almeida OP, Garrido GJ, Lautenschlager NT, et al: Smoking is associated with reduced cortical regional gray matter density in brain regions associated with incipient Alzheimer disease. Am J Geriatr Psychiatry 2008;16:92-98.
50.
Fratiglioni L, Paillard-Borg S, Winblad B: An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004;3:343-353.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.